AngioDynamics Inc (ANGO)vsBecton Dickinson and Company (BDX)
ANGO
AngioDynamics Inc
$12.13
-1.06%
HEALTHCARE · Cap: $479.00M
BDX
Becton Dickinson and Company
$195.16
+0.07%
HEALTHCARE · Cap: $52.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 6810% more annual revenue ($22.48B vs $325.38M). BDX leads profitability with a 4.2% profit margin vs -10.1%. BDX appears more attractively valued with a PEG of 1.11. BDX earns a higher WallStSmart Score of 52/100 (C-).
ANGO
Hold40
out of 100
Grade: D
BDX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+38.2%
Fair Value
$18.39
Current Price
$12.13
$6.26 discount
Margin of Safety
+10.7%
Fair Value
$202.19
Current Price
$195.16
$7.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -20.1% — below average capital efficiency
ROE of 3.9% — below average capital efficiency
4.2% margin — thin
Premium valuation, high expectations priced in
Earnings declined 31.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANGO
The strongest argument for ANGO centers on Debt/Equity. PEG of 1.41 suggests the stock is reasonably priced for its growth.
Bull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bear Case : ANGO
The primary concerns for ANGO are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : BDX
The primary concerns for BDX are Return on Equity, Profit Margin, P/E Ratio. A P/E of 44.6x leaves little room for execution misses. Thin 4.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
ANGO profiles as a turnaround stock while BDX is a value play — different risk/reward profiles.
ANGO carries more volatility with a beta of 0.30 — expect wider price swings.
ANGO is growing revenue faster at 6.9% — sustainability is the question.
BDX generates stronger free cash flow (509M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (52/100 vs 40/100). ANGO offers better value entry with a 38.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AngioDynamics Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?